CD80 and renal cell carcinoma: A phase I study demonstrated safety of a vaccine against renal cell carcinoma (RCC) containing tumor cells expressing RCC26/IL-7/CD80; while they did not observe increased Th1 specific immune responses, they did find higher levels of Th2 mediated IL-10 expression in patients who responded [76].